New Stock News | SenseTime Group Plans to List in Hong Kong CSRC Requires Supplemental Information on Whether There is Shareholding in History

The China Securities Regulatory Commission issued the "Requirements for Supplementary Materials for Overseas Issuance and Listing (February 9, 2026 March 2, 2026)". The International Department of the China Securities Regulatory Commission has issued supplementary material requirements for 7 companies, among them, requesting Xiansheng Zaiming to provide supplementary explanations on the prices of each capital increase and equity transfer, the pricing basis, whether the capital has been paid up, the existence of unfulfilled capital obligations, capital diversion, and any flaws in the capital contribution method; as well as whether there has been any shareholder holding shares on behalf of others throughout the company's history. It is reported that Xiansheng Zaiming has submitted a listing application to the Hong Kong Stock Exchange Main Board on January 9, with Morgan Stanley and CICC as joint sponsors. The China Securities Regulatory Commission has requested Xiansheng Zaiming to provide clarification on the following matters, and to have the lawyers verify and provide clear legal opinions: 1. Regarding changes in equity: (1) Please explain the prices of each capital increase and equity transfer, the pricing basis, whether the capital has been paid up, the existence of unfulfilled capital obligations, capital diversion, flaws in the capital contribution method, and provide a definitive conclusion on the legality and compliance of each equity change; (2) Please explain whether there has been anyone holding shares on behalf of others throughout the company's history; (3) Provide a clear opinion on whether the implemented employee shareholding plan and equity incentive plan are legal, compliant, and whether there is any improper benefit transfer. 2. Whether the business scope and actual business of the company and its subsidiaries involve the development and application of human stem cells, gene diagnostic and treatment technologies as listed in the "Special Management Measures for Foreign Investment Access (Negative List) (2024 Edition)", and provide clear evidence. 3. Whether the shares held by the shareholders participating in this "full circulation" have been pledged, frozen, or have other defects in rights. 4. In accordance with the requirements of the "Regulatory Rules Application Guide - Overseas Issuance and Listing No. 2", please explain the relationship between the main business of the controlling shareholder and the main business of the company. The prospectus shows that Xiansheng Zaiming focuses on the research, development, and commercialization of innovative cancer drugs. It currently has five commercialized innovative drugs, over 15 high-potential candidate drugs in clinical and IND declaration preparation stages, as well as multiple discovery projects. According to a Zhaoshi consulting report, in 2025, the company completed three external licensing transactions, ranking first and fourth in terms of the number of cancer asset transactions and total transaction value in SINO BIOPHARM.